Table 1.
Copeptin as a predictor of all-cause mortality and/or heart failure hospitalisation in the 86 patients with HFPEF in KaRen
| Parameter | All-cause mortality or HF hospitalisation (n=36) |
|||
|---|---|---|---|---|
| n | HR | 95% CI | p Value | |
| Copeptin | 86 | 1.56 | 1.03 to 2.38 | 0.037 |
| Copeptin (adjusted for age) | 86 | 1.56 | 1.03 to 2.38 | 0.038 |
| Copeptin (adjusted for gender) | 86 | 1.58 | 1.04 to 2.40 | 0.032 |
| Copeptin (adjusted for GFR) | 85 | 1.69 | 0.94 to 3.01 | 0.078 |
| Copeptin (adjusted for NT-proBNP) | 85 | 1.39 | 0.91 to 2.12 | 0.125 |
| Copeptin (adjusted for age, gender and NT-proBNP) | 85 | 1.40 | 0.92 to 2.14 | 0.119 |
GFR, glomerular filtration rate; HF, heart failture; HFPEF, heart failturewith preserved ejection fraction; KaRen, Karolinska Rennes Study; NT-proBNP, N-terminal pro-brain natriuretic peptide.